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Abstract
Background: Genome-wide association studies and subsequent replication studies have shown that single
nucleotide polymorphisms (SNPs) in the chromosomal region 8q24 are associated with colorectal cancer
susceptibility.
Methods: We examined 11 SNP markers in the 8q24 region between 128.47 and 128.54 Mb, using a total of 1,987
colon cases and 2,339 controls who self-reported as white from two independent, well-characterized study
populations. Analysis was performed separately within each study, and combined using random effects meta-
analysis. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) and to
test for effect modification by known colon cancer risk factors. We also performed a meta-analysis combining our
results with previous studies.
Results: We observed evidence of association for four SNPs in low to high linkage disequilibrium (r
2 ranging from
0.18 to 0.93) localized in a 16.2 kb region defined by rs10505477 and rs1056368. The combined results for our two
studies of colon cancer showed an OR of 1.10 (95% CI: 1.01-1.20, Ptrend = 0.023), and a meta-analysis of our results
with previously reported studies of colon and colorectal cancer strongly support the association for this SNP
(combined OR for rs6983267 = 1.21, 95% CI: 1.18-1.24, p = 5.5 × 10
-44). We did not observe any notable evidence
of effect modification by known colon cancer risk factors, and risk did not differ significantly by tumor site or stage.
Conclusions: Our study confirms the association between polymorphisms on chromosome 8q24 and colon cancer
risk and suggests that the susceptibility locus in region 8q24 is not strongly modified by various lifestyle,
environmental, and demographic risk factors for colon cancer.
Background
Colorectal cancer is the third leading cause of cancer
and cancer death for both men and women in the Uni-
ted States [1]. At least 20%, and perhaps as much as
one-third, of colorectal cancer is attributable to inher-
ited factors [2]. High-penetrance mutations, such as
those of the adenomatous polyposis coli gene (APC) and
DNA mismatch-repair genes, account for < 5% of the
cases and it is expected that a large proportion of the
inherited susceptibility is likely to be explained by
numerous low-penetrance variants in combination with
susceptibility to diet, lifestyle, and environmental expo-
sures. Numerous candidate gene studies have been per-
formed for colorectal cancer, and a large number have
detected associations. However, candidate gene studies
have not been consistently replicated [3] and establish-
ing the role of such low-penetrance variants with cer-
tainty has proved challenging [4].
The ability to conduct genome-wide association stu-
dies that include hundreds of thousands of single
nucleotide polymorphisms (SNPs) has considerably
improved this situation. Genome-wide scans and
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have shown that SNPs in the chromosomal region 8q24
are associated with prostate [5-14], breast [15], urinary
bladder [16], and colorectal cancer [8,17-32]. For pros-
tate cancer, three regions of 8q24 spanning in total a
430 Mb region were initially found to be independently
associated, with recent studies identifying two additional
regions [14,33]. In contrast, for colorectal cancer, statis-
tically significant associations were initially reported
only for an approximately 60 kb region of high linkage
disequilibrium between chromosomal location 128.475
and 128.545 Mb. Although the strength of association
between genetic variation in this region and colorectal
cancer is modest, with reported per-allele odds ratios
(ORs) ranging from 1.11 to 1.28, the region may contri-
bute importantly to the susceptibility of colorectal can-
cer due to the high frequency of the variant. The minor
allele frequency of the variant showing highest signifi-
cance (rs6983267) is about 49-50% in European and
European American populations [21,29,32]; 85-90% in
African American populations [9,22]; and 30-35% in
Japanese, Japanese American and Native Hawaiian
populations [9,24].
In this paper, we followed up these intriguing findings
by examining 11 SNP markers in the 8q24 region
between positions 128.47 and 128.54 Mb in two inde-
pendent, well-characterized study populations. In addi-
tion, we performed a meta-analysis of the rs6983267
variant in relation to risk of colon and colorectal cancer.
Further, we characterized the epidemiologic architecture
of this susceptibility locus by testing for interactions
with known environmental risk factors for colorectal
cancer, and by examining associations by tumor stage
and site.
Methods
The study uses colon cancer cases and controls from
two previously described study populations: a multi-cen-
ter population-based case-control study focusing on
Diet, Activity and Lifestyle (DALS) and colon cancer
[34] and a nested case-control study of colon cancer
within the Women’s Health Initiative (WHI) Observa-
tional Study [35-38].
Cases and controls in the multi-center DALS were
recruited from three sites: the Kaiser Permanente Medi-
cal Care Program (KPMCP) of Northern California; an
eight-county area in Utah; and the metropolitan Twin
Cities area of Minnesota [34]. Cases were eligible if they
were between 30-79 years of age at the time of diagno-
sis, with first primary colon cancer (International Classi-
fication of Diseases for Oncology [ICD-O] Ed.2. codes
18.0 and 18.2-18.9) between October 1991 and Septem-
ber 1994, and displayed sufficient mental competence to
complete the interview. Cases with tumors in the
rectosigmoid junction or rectum and cases with a
pathology report indicating Familial Adenomatous Poly-
posis, Crohn’s disease, or ulcerative colitis were
excluded. A rapid-reporting system was used to identify
all incident cases, with a majority being interviewed
within 4 months of diagnosis. Response and participa-
tion proportions have been described previously [34]. Of
the cases who were asked to participate in the study,
76% (n = 1,993) cooperated, of whom 83% (n = 1,676)
provided a blood sample for DNA extraction.
Controls in DALS were frequency matched to cases by
5-year age groups and sex. Controls from KPMCP were
randomly selected from membership lists. In Utah, con-
trols who were under 65 years of age were randomly
selected from lists generated using random-digit dialing
and driver license lists, and those 65 years of age and
older were randomly selected from Health Care Finan-
cing Administration lists. In Minnesota, control partici-
pants were identified from drivers license or state
identification lists. Of the controls asked to participate,
64% (n = 2,410) cooperated, of whom 85% (n = 2,004)
provided a blood sample for DNA extraction. Our pri-
mary analysis is restricted to 1,461 cases and 1,813 con-
trols who self-reported as white.
The WHI Observational Study (OS), a prospective
cohort study conducted in conjunction with the WHI
randomized Clinical Trials (CT), recruited 93,676 post-
menopausal women living in proximity to 40 clinical
centers located across the USA [35-38]. Between Oct. 1,
1993, and Dec. 31, 1998, women aged 50 to 79 years
were recruited into the WHI, mostly by age- and
women-targeted mass mailings and announcements in
the media. Exclusion criteria for both the OS and CT
included participation in existing randomized trials,
medical conditions predictive of a survival of less than 3
years, and conditions inconsistent with study participa-
tion and adherence. The clinical trials had additional
eligibility requirements and the OS is substantially com-
prised of women who were ineligible for the CT or who
did not want to be randomly assigned to an interven-
tion. Cancer outcomes were initially assessed annually
by mail or phone questionnaires. Self-reported colon
cancer was adjudicated by trained physicians based on
medical records and pathology reports at the clinical
centers and centrally confirmed by blinded review at the
WHI Coordinating Center [35]. Within this cohort, we
conducted a nested case-control study among women
who provided a blood sample for DNA extraction and
did not refuse genetic testing. The censor date was Sep-
tember 12 2005. At that time, the mean follow-up time
was 7.6 years with 2.2% lost to follow-up. Cases were
defined as invasive incident colon cancer cases (ICD-O
site codes 153.0-153.4 and 153.6-153.9). Control partici-
pants were randomly selected and individually matched
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African American, Hispanic, other), hysterectomy status,
and prevalent condition at baseline using risk set sam-
pling. Our primary analysis is restricted to 526 matched
pairs of colon cancer cases and controls, representing all
cases diagnosed before September 12, 2005 who self
reported as white and had genotype data available for
both the case and their matched control.
All participants included in this study provided written
informed consent, and the study was approved by the
human subjects committee at each participating
institution.
For the DALS study, in-person interviews were used
to collect demographic, dietary, and lifestyle data
[39,40]. Study participants were asked about their life-
style during the year, two years prior to the date of diag-
nosis or selection. During the in-person interview,
information was collected on dietary intake, physical
activity, medical history and drug use, demographic fac-
tors, smoking, reproductive history (for women), and
family history of cancer and colorectal polyps. Dietary
intake was ascertained using a diet-history question-
naire, which was modified from the questionnaire
designed and validated for the Coronary Artery Risk
Development in Young Adults (CARDIA) study [41].
For WHI, information on demographics, smoking and
alcohol use, medical history, lifestyle/behavioral factors,
family history of cancer, reproductive history, and details
of physical activity, among other risk factors, were
obtained by standardized self-administered question-
naires at baseline. Measurements for weight, height,
waist, and hip were ascertained during a baseline physi-
cal examination. Details on medication usage, including
non-steroidal anti-inflammatory drugs (NSAIDs), post-
menopausal hormone (PMH), and vitamin and mineral
supplements were collected from an interview-adminis-
tered questionnaire during the baseline clinical visit.
Dietary intake was assessed using a self-administered,
122-item Food Frequency Questionnaire at baseline.
Clinical and epidemiologic data was harmonized
across the two studies through a systematic evaluation
of individual study questionnaires, protocols, and data
dictionaries. The reference date for DALS is two years
prior to the date of diagnosis. The reference date for
WHI is the baseline questionnaire date. We selected
seven risk factors that are consistently shown to be asso-
ciated with colon cancer risk. For family history, sub-
jects were classified as having at least one 1
st degree
relative (parents, siblings and children) with colorectal
cancer versus no 1
st degree relatives with colorectal can-
cer. Non-smokers were defined as individuals smoking
less than 100 cigarettes in their lifetime, and smokers
were classified as either current or former smokers.
Body mass index (BMI; kg/m
2) was calculated based on
baseline measurements of height and weight for the
WHI study, and on self-report of height and weight on
a reference date (~2 years before diagnosis for cases and
interview for controls) in DALS. Our examination of
effect modification by BMI was restricted to men and
estrogen-positive women (e.g. premenopausal women
and postmenopausal women currently taking PMH). For
physical activity, subjects were divided into those with
one or more hour of vigorous/strenuous leisure physical
activity per week, and those without at least one hour of
vigorous/strenuous leisure physical activity per week.
For NSAID use, we divided subjects into current NSAID
users versus not-current NSAID users. Effect modifica-
tion by PMH was examined only in post-menopausal
women and we compared ever versus never use of
PMH. Current alcohol consumption was dichotomized
to less than one drink per week versus one or more
drinks per week.
Genotyping was performed using genomic DNA
extracted from peripheral blood lymphocytes or from
immortalized cell lines. The genotyping lab was blinded
to case/control status and duplicate quality-control sam-
ples were interspersed among plates (341 duplicates
from 226 different subjects). All genotyping was per-
formed by MALDI-TOF mass spectrometry on the
Sequenom MassARRAY Compact platform using the
iPLEX Gold (low-plex) reaction. In total, we received
clear genotyping results for 11 out of 14 SNPs. The
remaining three SNPs (rs7002225, rs6998061 and
rs6999921) were excluded for having discordances with
the HapMap positive-control samples and/or severe
departures from HWE (p < 1 × 10
-4). In all three cases,
one of the homozygous genotype calls was missing. The
call rate was > 95% for 10 out of the 11 SNPs, and the
11
th SNP (rs6983267) had a call rate of 94.8%. Blinded
duplicates displayed > 99% concordance for all SNPs.
Using an exact test, the allele frequencies among con-
trols for self-reported whites did not deviate from HWE
for any SNP at p = 0.01. HWE for all SNPs for both the
self-reported whites and the full population are pre-
sented in Additional file 1.
To estimate the association between genetic variants
in the 8q24 region and colon cancer risk we calculated
odds ratios (ORs) and 95% confidence intervals (95%
CIs) using a two-stage pooled analysis, which allow us
to combine results for the two studies, even though they
have different designs [42,43]. Stage 1 used a model
appropriate to each study design with study-specific
confounders. Stage 2 used a random effects meta-analy-
sis to combine the results for the two studies. For the
individually matched data in the WHI nested case-con-
trol study, we used conditional logistic regression analy-
sis to account for matching. For DALS data we used
logistic regression adjusted for age, sex, and study
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cation when including non-white subjects in each study,
we restricted our primary analyses to subjects who self-
reported as white. Individual SNPs were coded based on
the log-additive model, including a single variable,
coded as the number of copies of the minor allele. Stage
2 combined the individual study-specific adjusted log-
ORs using a linear mixed-effects model, which were
then converted to ORs and 95% CIs. We also examined
each SNP using a dominant and recessive model. Haplo-
type frequencies for cases and controls were compared
using the HAPSTAT software [44]. Although we tested
11 SNPs, we did not adjust for multiple testing as this
study is set up as a replication and fine-mapping study
to confirm previous findings and narrow down the spe-
cific region of association. However it is important to
evaluate our findings in light of the number of SNPs
tested. A conservative Bonferroni correction for 11
SNPs would lead to a p-value threshold of 0.05/11 =
0.0045.
For SNPs that showed associations at alpha level 0.05
and no evidence of between-study heterogeneity, we
explored interactions between genetic variations and
known risk factors for colon cancer. Specifically, we
conducted stratified analyses and tests for multiplicative
interaction with inclusion of cross-product terms in the
regression models. The statistical significance of interac-
tion terms was assessed using a likelihood-ratio test
comparing the full model including the interaction term
to the nested model that included only the main effects
and adjustment variables. We also did a combined case-
only and case-control analysis to examine evidence for
gene-environment interactions [45].
Because risk factors for colon cancer can differ by
anatomic site, we used polytomous regression analysis
to examine the association between variants and cancer
subtypes defined by site (proximal colon: cecum,
ascending colon, hepatic flexure of colon and transverse
colon; distal colon: splenic flexure, descending colon,
and sigmoid) and by SEER staging categories (localized,
regional, or distant). In addition to polytomous regres-
sion, we also used the generalized odds ratio to examine
stage, ranking localized, regional and distant disease in
that order [46].
We conducted a meta-analysis including all published
studies of the 8q24 variant rs6983267 and colorectal
cancer. Because rs6983267 and rs10505477 are in high
linkage disequilibrium (LD; r
2 =0 . 9 3i nt h eH a p M a p
CEU population), and because some studies have used
them as tags for one another [32], we also searched for
studies that examined the rs10505477 variant. Since it
may be argued that high LD in HapMap does not justify
switchability of the two alleles, we present the results
for rs6983267 only as our primary analysis. Studies were
identified through searches of PubMed and Web of
Science using the search term “8q24” and either “colon
cancer” or “colorectal cancer”.W ea l s oe x a m i n e dW e b
of Science for all papers citing the original paper by
Haiman and colleagues [8]. The last search was con-
ducted on March 31, 2010. All papers were screened by
one investigator (CMH), to assess whether they had
association level data in a sample of at least 100 cases
and 100 unrelated controls. Family based studies,
including sib-pair analysis were excluded. No other
additional screening or eligibility criteria were used. For
each paper we extracted the following information into
a table: author name, year of publication, geographic
location, race/ethnicity, sample size and reported allelic
or log-additive OR and 95% CI. Risk estimates from
individual studies were combined and the corresponding
summary 95% CI and p-values were obtained under a
random-effects meta-analysis model [47,48]. Forest plots
were used to display the results from individual studies,
as well as the summary results. The statistical signifi-
cance of between-study heterogeneity was evaluated
using Cochran’s Q statistic [47-49]. If the p-value was
less than 0.10, the heterogeneity was considered statisti-
cally significant. We also quantified heterogeneity using
the I
2 metric. I
2 takes values between 0 percent and 100
percent, with higher values indicating higher levels of
heterogeneity [50]. Potential bias was assessed by com-
paring results for small and large studies using Egger’s
test and visual inspection of funnel plots [51], and we
examined the trend in risk estimates over time using
cumulative meta-analysis [52]. As a sensitivity analysis,
we pre-specified that we would perform a meta-analysis
combining studies that looked at rs6983267 and
rs10505477, in addition to our primary meta-analysis
only of studies examining the rs6983267 SNP. Because
of the differences in allele frequencies observed across
populations [9], we present meta-analysis results both
for all studies combined, and for studies stratified by
primary race/ethnicity. We also performed an ad hoc
analysis including the study that used a sib-pair analysis
and did not meet our initial inclusion criteria [26].
Results
Table 1 shows characteristics of the study participants.
By design, the WHI study comprises only female sub-
jects and is restricted to subjects over age of 50. The
DALS study had 53.1% male controls and 56.3% male
cases, with 91.5% of controls and 92.7% of cases over
the age of 50. The two studies show similar patterns for
smoking and BMI, with both studies showing a higher
proportion of cases who ever smoked and who had BMI
>2 5 .D A L Ss h o w sag r e a t e rd ifference between cases
and controls on family history of colorectal cancer and
recent NSAID use, with a higher frequency of a positive
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use in the controls. Both studies show a slightly higher
proportion of cases with < 1 hour of physical activity
per week and a higher proportion of female controls
using PMH, with higher overall physical activity levels
in DALS and higher PMH use in the WHI study. For
DALS, the regional distribution of cases was 44.8% from
Northern California, 38.6% from Minnesota and 16.5%
from Utah, and the distribution of controls was 37.5%
from Northern California, 43.6% from Minnesota and
Table 1 Characteristics of study participants, by study
DALS WHI
Controls Cases Controls Cases
Characteristic n (%) n (%) n (%) n (%)
N 1813 1461 526 526
Gender
Male 963 (53.1) 822 (56.3) 0 0
Female 850 (46.9) 639 (43.7) 526 (100) 526 (100)
Age
30-39 40 (2.1) 21 (1.4) 0 0
40-49 116 (6.4) 86 (5.9) 0 0
50-59 292 (16.1) 270 (18.5) 72 (13.7) 73 (13.9)
60-69 622 (34.3) 507 (34.7) 229 (43.5) 229 (43.5)
70-79 743 (41.0) 577 (39.5) 225 (42.8) 224 (43.6)
Family History of CRC
No 1st degree relative 1637 (90.3) 1213 (83.0) 384 (80.5) 381 (77.1)
≥1 1st degree relatives 176 (9.7) 248 (17.0) 93 (19.5) 113 (22.9)
Cigarette Smoker
Never 852 (47.0) 597 (41.0) 252 (48.2) 233 (44.8)
Former 715 (39.4) 649 (44.5) 240 (45.9) 252 (48.5)
Current 246 (13.6) 212 (14.5) 31 (5.9) 35 (6.8)
BMI
< 25 720 (39.8) 485 (33.3) 199 (38.3) 186 (35.8)
≥25 1090 (60.2) 971 (66.7) 320 (61.7) 334 (64.2)
Physical Activity
< 1 hour per week 1089 (60.1) 937 (64.2) 251 (48.3) 255 (49.0)
≥1 hours per week 724 (39.9) 523 (35.8) 269 (51.7) 265 (51.0)
NSAID use
Not Current User 1098 (60.0) 1018 (69.7) 362 (68.8) 367 (69.8)
Current User 715 (39.4) 443 (30.3) 164 (31.2) 159 (30.2)
Hormone Replacement Therapy Use
Not Current User 503 (69.2) 422 (76.1) 311 (59.2) 345 (65.7)
Current User 224 (30.8) 133 (23.9) 214 (40.8) 180 (34.3)
Alcohol consumption
< 1 drink a week 1025 (56.5) 825 (56.5) 298 (56.8) 324 (62.0)
≥1 drinks per week 788 (43.5) 636 (43.5) 227 (43.2) 199 (38.1)
Tumor Stage
Localized NA 538 (38.5) NA 212 (40.3)
Regional NA 702 (50.2) NA 228 (43.4)
Distant NA 117 (8.4) NA 67 (12.7)
Missing/Unknown NA 103 (2.9) NA 19 (3.6)
Tumor Site
Distal Colon NA 720 (49.3) NA 143 (27.2)
Proximal Colon NA 705 (48.3) NA 361 (68.6)
Missing NA 36 (2.5) NA 22 (4.2)
DALS = Diet Activity and Lifestyle Study; WHI = Women’s Health Initiative; N = total sample size; CRC = colorectal cancer; BMI = Body mass index; NSAID = Non-
steroidal anti-inflammatory drugs
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cases was 23.7% from the Midwest, 27.2% from the
North East, 21.5% from the South and 27.6% from the
West, and the distribution of controls was 25.4% from
the Midwest, 23.8% from the North East, 22.5% from
the South and 28.3% from the West.
W eg e n o t y p e d1 1S N P s ,a l lo fw h i c hw e r ei nH W E
within the control population of subjects who self-
reported as white for both studies (p-value for exact test
> 0.05). Four SNPs (rs10505477, rs10808555, rs6983267
and rs10956368) showed an increased risk of colon can-
cer at the alpha = 0.05 level in the combined analysis of
individuals who self-report as white, with ORs ranging
from 1.1 to 1.3 (Table 2). None of the SNPs would be
significant if we used a correction for multiple testing
for the 11 SNPs. Two of the four SNPs (rs10505477 and
rs6983267) were also associated in DALS alone at the
alpha = 0.05 level, and none were statistically signifi-
cantly associated in the analysis restricted to the WHI
samples (Table 1). All four SNPs had a similar magni-
tude of association across the two studies, with an I
2
m e a s u r eo f0a n dh e t e r o g e n e i t y p-values > 0.5, indicat-
ing no evidence of between-study heterogeneity. A fifth
SNP (rs9297756) was associated with an increased risk
in DALS (OR = 1.22; 95% CI: 1.07-1.39) but showed a
trend toward decreased risk in the WHI (OR = 0.93;
95% CI: 0.74-1.18). This SNP showed high between-
study heterogeneity (I
2 = 78.4%, heterogeneity p =
0.032). We did not observe any additional significant
SNPs when we considered dominant or recessive models
of inheritance. Further, the haplotype frequencies did
not show statistically significant differences between
cases and controls (see Additional file 2).
The four SNPs with a statistically significant associa-
tion and low between-study heterogeneity are located in
a 16,207 bp region (between positions 128,476,625 and
128,492,832) and show a range from low to high linkage
disequilibrium (r
2 range: 0.18-0.93). LD was strongest
between rs6983267 and rs10505477 (r
2 =0 . 9 3 )( F i g u r e
1). These SNPs show slightly stronger evidence for asso-
ciation in men compared to women (see Additional file
3). For rs6983267, the OR for men is 1.16 (95% CI:
1.02-1.33, p = 0.03) and the OR for women (WHI and
DALS combined) is 1.07 (95% CI: 0.97-1.87, p = 0.20).
However, this is not a statistically significant difference
in either DALS alone, or in the combined sample.
Results were also similar when we included subjects that
did not self-report as white (126 cases and 126 controls
for WHI and 139 cases and 135 controls for DALS),
with an OR of 1.12 (95% CI: 0.97-1.30, p = 0.14) for
WHI and 1.12 (95% CI: 1.02-1.23, p = 0.02) for DALS.
Some of the SNPs showed differences in strength of
association when stratified by colon cancer risk factors.
For example, if we look at effect modification by BMI
for rs10808555, there is a trend towards stronger asso-
ciation between the SNP in males and estrogen-positive
women with a high BMI (OR = 1.19; 95% CI: 1.03-1.18)
than in males and estrogen-positive women with a low
BMI (OR = 0.96; 95% CI: 0.79-1.16, p-interaction =
0.08); however, we did not observe any evidence for sta-
tistically significant gene-environment interactions (see
Additional file 3). We had similar results in the case-
only analysis (results not shown). There was a slight ten-
d e n c yf o rt h ea s s o c i a t i o n st ob es t r o n g e ri nd i s t a n t -
stage, rather than localized or regional, cancers but,
again, these differences were not larger than would be
expected by chance (see Additional file 4). Our stage
analysis was also not significant when we used the gen-
eralized OR. The associations did not differ notably by
tumor site. One SNP, rs10109622 showed a potential
association between the minor allele and decreased risk
of proximal colon cancer (OR = 0.88; 95% CI: 0.77-
0.99), with a non-significant odds ratio greater than 1.0
for distal colon cancer (OR = 1.07; 95% CI: 0.75-1.22),
b u tt h i sf i n d i n gi sn o ts i g n i f i cant in either subsite once
you adjust for multiple testing (see Additional file 5).
Results for the meta-analysis are shown in Figure 2.
This analysis is based on our data along with that of
17 other studies from 13 publications identified
through our literature review for rs6983267
[9,17-20,22-25,27,29-31]. One study was excluded
because it used a sib-pair analysis [26]. When data were
combined across all studies for rs6983267, there was
strong evidence for an association between rs6983267
and colorectal cancer risk (OR = 1.21; 95% CI: 1.18-
1.24; p = 5.5 × 10
-44); with no evidence of between-
study heterogeneity (I
2 = 0.0%; heterogeneity p = 0.746).
There was also no evidence for heterogeneity between
racial/ethnic groups (p = 0.76), although the number
and size of studies was relatively small for non-Eur-
opean/European American populations. A similar asso-
ciation was found when we also included studies that
examined the rs10505477 variant [21,32] (OR = 1.19;
95% CI: 1.17-1.22; p = 2.2 × 10
-53; see Additional file 6);
again, there was no evidence for between-study hetero-
geneity (I
2 = 0.0%; overall heterogeneity p = 0.540). Our
results are also consistent with those reported for the
rs7014346 SNP in this region (OR = 1.19; p = 8.6 × 10
-
26) [28]. There was no evidence of differences between
large and small studies based on Eggar’s test (p = 0.44)
and visual inspection of funnel plots. The cumulative
meta-analysis shows that while the original estimate is
slightly higher, the estimates have held steady in the
r a n g eo f1 . 2 1t o1 . 2 3( s e eA d d i t i o n a lf i l e7 ) .A sapost
hoc analysis, we also included the study by Poynter and
colleagues [26]. This study had been excluded on pre-
specified inclusion/exclusion criteria because it used a
sib-pair analysis rather than unrelated cases and
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DALS WHI Combined
SNP Location Allele* MAF Genotype Cases Controls OR (95% CI) p MAF Genotype Cases Controls OR (95% CI) p OR (95% CI) p I
2
rs16902148 128476181 G®A 0.05 GG 1328 1615 1 (Ref) 0.05 GG 595 589 1 (Ref)
GA 128 184 0.86 (0.68-1.09) GA 46 57 0.81 (0.54-1.21)
AA 2 3 0.84 (0.14-5.05) AA 1 3 0.33 (0.03-3.18)
log additive 0.86 (0.68-1.08) 0.203 log additive 0.75 (0.50-1.13) 0.168 0.83 (0.68-1.02) 0.073 0.0%
rs10505477 128476625 C®T 0.49 CC 307 424 1 (Ref) 0.50 CC 144 162 1 (Ref)
CT 741 912 1.13 (0.95-1.35) CT 323 328 1.10 (0.84-1.44)
TT 405 461 1.23 (1.01-1.50) TT 169 156 1.21 (0.88-1.65)
log additive 1.11 (1.00-1.22) 0.045 log additive 1.08 (0.91-1.27) 0.384 1.10 (1.01-1.20) 0.026 0.0%
rs10808555 128478693 G®A 0.33 GG 604 797 1 (Ref) 0.33 GG 278 285 1 (Ref)
GA 671 804 1.10 (0.95-1.28) GA 279 293 0.97 (0.77-1.23)
AA 182 198 1.21 (0.97-1.52) AA 81 67 1.24 (0.86-1.79)
log additive 1.10 (0.99-1.22) 0.067 log additive 1.08 (0.91-1.28) 0.395 1.10 (1.00-1.20) 0.047 0.0%
rs6983267 128482487 T®G 0.48 TT 284 400 1 (Ref) 0.49 TT 137 149 1 (Ref)
TG 740 899 1.17 (0.97-1.40) TG 303 326 1.00 (0.76-1.33)
GG 424 486 1.23 (1.00-1.51) GG 174 158 1.19 (0.87-1.63)
log additive 1.11 (1.00-1.22) 0.048 log additive 1.09 (0.92-1.29) 0.336 1.10 (1.01-1.20) 0.023 0.0%
rs10956368 128492832 C®T 0.41 CC 472 634 1 (Ref) 0.39 CC 218 236 1 (Ref)
CT 718 859 1.13 (0.96-1.32) CT 295 316 1.00 (0.78-1.28)
TT 260 301 1.16 (0.95-1.43) TT 115 91 1.37 (0.98-1.91)
log additive 1.09 (0.98-1.20) 0.100 log additive 1.12 (0.94-1.32) 0.201 1.10 (1.01-1.20) 0.035 0.0%
rs7005829 128504126 C®T 0.29 CC 703 925 1 (Ref) 0.28 CC 350 328 1 (Ref)
CT 624 722 1.14 (0.99-1.32) CT 237 270 0.82 (0.65-1.03)
TT 129 152 1.12 (0.86-1.44) TT 51 48 1.00 (0.66-1.53)
log additive 1.09 (0.98-1.21) 0.113 log additive 0.94 (0.78-1.13) 0.523 1.03 (0.90-1.19) 0.647 53.4%
rs9297756 128509349 C®T 0.15 CC 980 1290 1 (Ref) 0.16 CC 462 450 1 (Ref)
CT 428 458 1.23 (1.05-1.44) CT 158 181 0.84 (0.65-1.08)
TT 46 42 1.42 (0.92-2.17) TT 15 11 1.36 (0.62-3.01)
log additive 1.22 (1.07-1.39) 0.004 log additive 0.93 (0.74-1.18) 0.570 1.08 (0.83-1.41) 0.547 78.4%
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5Table 2 Associations between 8q24 SNPs and risk of colon cancer (Continued)
rs12334695 128523110 T®C 0.38 TT 522 684 1 (Ref) 0.38 TT 252 245 1 (Ref)
TC 678 833 1.08 (0.93-1.26) TC 286 304 0.90 (0.71-1.15)
CC 235 268 1.16 (0.94-1.43) CC 95 89 1.04 (0.74-1.46)
log additive 1.08 (0.97-1.19) 0.148 log additive 1.01 (0.85-1.19) 0.937 1.06 (0.97-1.16) 0.186 0.0%
rs10109622 128527333 C®T 0.23 CC 896 1077 1 (Ref) 0.23 CC 393 388 1 (Ref)
CT 478 622 0.92 (0.79-1.07) CT 203 220 0.91 (0.72-1.15)
TT 83 99 1.02 (0.76-1.39) TT 39 38 1.01 (0.63-1.62)
log additive 0.96 (0.86-1.08) 0.537 log additive 0.99 (0.82-1.20) 0.954 0.97 (0.88-1.07) 0.512 0.0%
rs10094059 128530789 G®C 0.24 GG 847 1030 1 (Ref) 0.25 GG 346 378 1 (Ref)
GC 523 677 0.94 (0.81-1.08) GC 258 221 1.28 (1.01-1.61)
CC 87 93 1.13 (0.83-1.53) CC 41 55 0.82 (0.53-1.26)
log additive 0.99 (0.88-1.11) 0.908 log additive 1.01 (0.84-1.22) 0.888 1.00 (0.90-1.10) 0.929 0.0%
rs7841264 128535996 C®T 0.18 CC 1009 1190 1 (Ref) 0.17 CC 449 444 1 (Ref)
CT 395 546 0.85 (0.73-0.99) CT 166 174 0.95 (0.74-1.22)
TT 50 59 1.01 (0.68-1.48) TT 15 22 0.68 (0.34-1.33)
log additive 0.90 (0.79-1.03) 0.118 0.17 log additive 0.93 (0.75-1.16) 0.526 0.91 (0.81-1.02) 0.095 0.0%
* Reference allele is listed first. Reference allele is the common allele for all SNPs but rs10505477 and rs6983267. Those two SNPs have minor allele as reference for better comparison with previously published
studies. DALS=Diet, activity and lifestyle study; WHI= Women’s Health Intitiative; MAF=minor allele frequency; p=p-value from test of trend with genotype coded 0/1/2. I-squared measures between study
heterogeneity. Associations significant at alpha level=0.05 are shown in bold.
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5controls; however, this was also the only study we found
that reported an estimated OR less than one (for the
clinic based samples). Inclusion of both the population
and clinic-based estimates from this study did not sub-
stantively change the estimate for association (OR =
1.19; 95% CI: 1.15-1.23; p = 5.1 × 10
-23), but did
increase overall heterogeneity (I
2 =2 6 . 5 % ;h e t e r o g e n e i t y
p = 0.14; see Additional file 6).
Discussion
This study confirms the previously reported association
between the 8q24 SNP rs6983267 and risk of colon can-
cer. The strength of association observed in our com-
bined examination of WHI and DALS is relatively
modest (OR = 1.10; 95% CI: 1.01-1.20; p = 0.023); how-
ever it is consistent with other studies as shown in our
meta-analysis for rs6983267 (OR: 1.21; 95% CI: 1.18-1.24;
p=5 . 5×1 0
-44). We examined 10 additional SNPs in the
region defined by 128.47 and 128.54 Mb and found the
associated interval at alpha = 0.05 to be localized in a
16.2 kb region defined by rs10505477 and rs1056368. We
did not observe any statistically significant interactions
between the 8q24 genotypes and known colon and color-
ectal cancer risk factors, and risk did not differ by tumor
site or tumor stage.
The results of our meta-analysis strongly support the
association between the rs6983267 variant, and SNPs in
LD with this variant, and colon and colorectal cancer.
Similar results are seen in both discovery GWAS studies
[28,29,32] and follow-up replication studies [17-27,30,31].
Although the allele frequency for rs6983267 varies across
racial/ethnic groups, the magnitude of the association
appears to be consistent for studies which include subjects
that do not self-report as white [26,27], and studies of
non-white populations (see Figure 2). However, to date,
most studies have focused on European and European
American populations and results for other populations
are based on only a handful of relatively small studies. The
current meta-analysis included studies of both colon and
colorectal cancer, combined studies that selected on family
history with studies that did not, and did not examine
alternative modes of inheritance, other than an additive
model. The studies that show the genotype contrasts are
generally consistent with an additive model. There is no
strong evidence for reporting bias for this meta-analysis
based on both funnel plots and cumulative meta-analysis;
however it is still possible that publication bias is prevent-
ing, or delaying, the publication of studies that are not
replicating the association [52]. It is also possible that
there is substantive bias, even in the presence of a symme-
trical funnel plot [53]. As more studies are published, with
more detailed information, it will be important to do addi-
tional meta-analyses that stratify on these factors, as well
as on key clinical and environmental risk factors. It will
also be important to continue to move forward with func-
tional follow-up studies to fully elucidate the causal
mechanism underlying this association.
Variants in the 8q24 region have been associated with
numerous cancers in addition to colorectal cancer. The
region was identified as a top hit in genome-wide asso-
ciation studies of prostate [5-10,12-14], breast [15], urin-
ary bladder [16] and colorectal cancers [8,29,32]. Follow-
up in studies of multiple cancers have confirmed these
findings [20] and have found additional associations for
kidney, thyroid, and larynx cancer [31], as well as can-
cers of the upper aerodigestive tract [54]. More refined
characterization of the 8q24 region shows that there are
multiple sub-regions, each defined by an underlying LD
structure [20,55]. These sub-regions show remarkable
allelic heterogeneity, with some regions influencing risk
for more than one cancer and some cancers being influ-
enced by variants from more than one region [9,20].
The region of 8q24 examined in this study was coined
as “Region 3” in a description of the multiple indepen-
dent regions impacting prostate cancer [9]. SNPs from
Region 3 have consistently been replicated for colorectal
cancer. Most studies examining SNPs outside of Region
3 do not find evidence for associations with colorectal
cancer [17,20,56], although one study did observe a sig-
nificant association in Region 5 [19] and another study
saw an association in Region 1 [18]. Initially Region 3
was defined as a 60 kb region spanning 128.48-128.54
Mb [9]. However, our study and others have narrowed
the region. Ghoussaini et al. [20] examined nine SNPs
across 8q24, including four in Region 3 and narrowed
the area showing association with colorectal cancer risk
Figure 1 Linkage disequilibrium in the 8q24 region between
128.47 and 128.54 Mb. Linkage disequilibrium coefficients (r
2)
between SNPs in the 8q24 region between 128.47 and 128.54 Mb.
As previously reported, r
2 is high for rs6983267 and rs10505477.
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Page 9 of 15to the 20 kb region between 128.48-128.50. Schafmayer
et al. [27] examined 45 SNPs across 8q24 with 19 SNPs
falling in Region 3. Their findings appeared to narrow
the colorectal cancer susceptibility region to a 17.3 kb
region defined by rs10505477 (at position 128,476,625)
and rs7014346 (at position 128,493,974). Notably, this
narrower region overlaps with the 16.2 kb region that
contains the four significantly associated SNPs in the
findings we report here, defined by rs10505477 (at posi-
tion 128,476,625) and rs1056368 (at position
128,492,832). In this paper we focused our meta-analysis
on rs6983267 because it is the most frequently pub-
lished SNP and the only variant with more than three
publications. If studies of 8q24 SNPs other than
rs6983267 continue to be published for colorectal can-
cer, it will be informative to perform meta-analyses of
Figure 2 Meta-analysis of the association between colorectal cancer and the 8q24 SNP rs6983267. Forest plot of effect sizes and inverse-
variance pooled estimates of the association between colorectal cancer risk and 8q24 SNP rs6983267. The symbol size indicates the weight for
each study, and lines indicate the confidence intervals. Studies are grouped by race/ethnicity. One study (indicated by an asterisk) reported more
than one racial/ethnic group, but is grouped with the European/European American studies, since that is the primary group (the percentage
Caucasian is 94-95% for both cases and controls). The study reported that similar results were found when they restricted to white/Caucasian
subjects. Results for rs6983267 were consistent across studies (I
2 = 0%; p-value for test of heterogeneity = 0.75).
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tional studies of 8q24 and colorectal cancer should
focus on variants in high LD with this narrow region.
We identified no statistically significant interactions
between genetic variants in 8q24 and various known
risk factors for colon cancer. Although some trends
were observed, we acknowledge that we have examined
a large number of factors, and our results should be
interpreted in the context of the large number of tests
performed. This finding of no significant interactions
is consistent with our previous study of 2,587 colorec-
tal adenoma and 547 colorectal cancer cases in Eur-
opean American populations, which also showed no
statistically significant interactions between rs6983267
and smoking, family history, age, or sex [17], as well as
a study of 481 colorectal cancer cases from Japan,
which showed no statistically significant interactions
between rs6983267 and smoking, drinking habits,
folate consumption, BMI, family history and exercise
[24]. Our finding of no difference based on family his-
tory of colorectal cancer is also consistent with a Pol-
ish case-control study of 779 colon cancer cases that
showed no interaction between rs6983267 and family
history [31], although that study did observe higher
OR estimates for cases with a 1
st degree relative with
cancer compared to those without at other cancer sites
(prostate, breast, bladder, larynx and lung). In addition,
a study of 438 cases from Utah, 405 from Sheffield and
249 from Leeds found notable differences in the
strength of association between the US site and the
two UK sites, suggesting potential gene-environment
interactions; however, this observation was not
explained by differences in family history or early
onset of disease. Given the potential for differences
between males and females, it is important to note
that the study did not observe effect modification by
sex [19]. These initial findings suggest that the sus-
ceptibility locus in region 8q24 is not strongly modi-
fied by plausible lifestyle, environmental, and
demographic risk factors for colorectal cancer. How-
ever, the number of studies that have explored such
interactions is small and may have been underpowered
for subtle effect modification. For example, our study
was powered to detect an interaction odds ratio of 1.3
or greater for an interaction between the 8q24 variants
and a dichotomous trait with a population prevalence
of 40 percent, which is similar to the frequency of the
environmental factors included in this analysis (see
Table 1). Given the low magnitude of association for
this variant, it is also possible that there will be a low,
but reproducible, interaction effect. Hence, the finding
of no effect modification still requires further corro-
boration. In particular, larger follow-up studies should
still consider potential effect modification by sex.
The 8q24 region is typically described as a gene desert
[57]. The 8q24 locus contains two transcripts with open
reading frames, which are both mapped to the region of
LD at 8q24.21: DQ515897 is a gene with unknown func-
tion and DQ486513 is a putative pseudogene of the
POU5F1, which encodes the transcription factor OCT4
[29]. However, the strongest candidate for 8q24 function
has always been the v-myc myelocytomatosis viral onco-
gene homolog gene (MYC), located about 350 kb telo-
meric of rs10505477 and rs6983267 [58]. MYC is an
important protooncogene, over-expressed in numerous
tumors, including colorectal tumors. Two recent studies
have provided several important insights into the func-
tional role of the rs6983267 variant [59,60]. First, they
showed preferential amplification of the haplotype con-
taining the rs6983207 G risk allele in colorectal tumors.
Second, they showed that the variant is located in a
transcriptional enhancer and that the G allele has
increased affinity for binding transcription factor 4
(TCF4). The TCF4 transcription factor plays a role in
activating the transcription of Wnt target genes. Third,
they showed that the rs6983267 region physically inter-
acts with the MYC promoter region. Together, these
results point to an impact on Wnt signaling and MYC
expression as a strong candidate for the biological
mechanisms connecting the rs6983267 variant to risk of
colorectal cancer [57,59,60]. In considering this mechan-
ism, it is important to note that, similar to an earlier
study [32], the recent studies did not observe differential
MYC expression in colon tumors based on 8q24 geno-
types. However, the studies many not be sensitive to
subtle effects that could be relevant for disease risk.
Further, the studies do not capture gene expression
throughout cancer development [57].
A major strength of this analysis was that we exam-
ined the genetic variation in the chromosome 8q24
region between 128.47 and 128.54 Mb in two well-char-
acterized studies with rich environmental data. This
allowed us to thoroughly investigate potential gene-
environment interactions and to examine the association
by tumor site and location. The two studies differ on
several key features. Most notably, the WHI is a
matched nested case-control study of older women,
whereas DALS is a population-based case-control study
of both women and men. However, with the exception
of rs9297756, the results were very consistent across the
two studies. Further, the rs9297756 finding does not
appear to be replicated in other studies, indicating that
it is likely to be a spurious finding in DALS rather than
a true heterogeneous finding across the two populations.
The studies also differed on how they assessed informa-
tion on environmental risk factors. Notably, for WHI we
used prospective ascertainment of baseline characteris-
tics, where as the DALS study had retrospective
Hutter et al. BMC Cancer 2010, 10:670
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Page 11 of 15ascertainment for a period two years before the diagno-
sis (cases) or selection (controls) date. There were also
some differences in how variables were ascertained. For
example, for NSAID use, DALS had detailed informa-
tion on past use and duration from questionnaire data
on all participants, while the WHI had information only
for current NSAID users. We were able to compare data
across studies by restricting our analysis to a compari-
son of current users at baseline or reference date and
current non-users at baseline or reference date. It is
possible that misclassification or lack of comparability is
responsible for our null findings for gene-environment
interactions. Future studies should also investigate
potential gene-environment interactions in other well-
characterized population-based studies.
Conclusions
Our results from a multi-center case-control study and
the WHI cohort replicate previous findings of an asso-
ciation between polymorphisms in a 16.2 kb region
located between 128.4766 and 128.4928 Mb on chromo-
some 8q24 and colon cancer risk. Taken as a whole, the
evidence for this association is consistent across studies
and populations. Most studies performed to date have
focused on European and European American popula-
tions. Additional replication in other ethnic and racial
groups is merited; because of differences in LD patterns
across populations, such studies should initially examine
variation across the entire 8q24 region. Our results do
not suggest evidence for gene-environment interactions
underlying this association.
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Additional file 1: Supplemental table S1: Exact Hardy-Weinberg p-
value in controls for self-reported whites and full population for
each study. Presents the HWE p-values for controls in WHI and DALS
separately, showing both the full population (all) and subjects who self
report as white.
Additional file 2: Supplemental table S2: Haplotype frequencies for
cases and controls. Presents the haplotype frequencies for cases,
controls and full population for both DALS and WHI.
Additional file 3: Supplemental table S3a: Associations between
rs10956368 and colorectal cancer stratified by CRC risk factors, by
study population. Supplemental table S3b: Associations between
rs6983267 and colorectal cancer stratified by CRC risk factors, by
study population. Supplemental table S3c: Associations between
rs10956368 and colorectal cancer stratified by CRC risk factors, by
study population. Each worksheet gives information on our
investigation of gene-environment interactions using stratified analysis
for a different SNP (rs10808555, rs6983267, rs10956368). Results are
presented for WHI, DALS and the combined study.
Additional file 4: Supplemental table S4: Associations between
8q24 SNPs and colon cancer/colorectal cancer risk stratified by
tumor stage. Presents results by tumor stage (localized, regional and
distant). Results are presented for WHI, DALS and the combined study.
Additional file 5: Supplemental table S5: Associations between
8q24 SNPs and colorectal cancer risk stratified by tumor site.
Presents results by tumor site (Total Colon, Distal Colon and Proximal
Colon). Results are presented for WHI, DALS and the combined study.
Additional file 6: Supplemental figure S1: Meta-analysis of the
association between colorectal cancer and the 8q24 SNPs
rs6983267 and rs10505477 including sib-pair analysis. Forest plot of
effect sizes and inverse-variance pooled estimates of the association
between colorectal cancer risk and 8q24 SNPs for a) both rs6983267 and
rs10505477; and b) including the study by Poynter et al which used sib-
pair analysis.
Additional file 7: Supplemental figure S2. Funnel plot and
cumulative meta-analysis plots for meta-analysis. Funnel plot of odds
ratio (OR) vs. standard error of OR for studies included in the meta-
analysis and cumulative meta-analysis plots for rs6983267 in European/
European American populations. These diagnostic plots can be used to
assess biases.
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